Your session is about to expire
← Back to Search
XMT-2056 for Breast Cancer
Study Summary
This trial tests a new drug to treat tumors that express a molecule called HER2.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are participants still being invited to join this experiment?
"Affirmative. Clinicaltrials.gov affirms that this medical research, which was first advertised on December 1st 2022 is actively looking for individuals to participate. A total of 144 people need to be enrolled from 3 distinct healthcare facilities."
To what extent does XMT-2056 pose a hazard to human health?
"Because it is still in its first phase of clinical trials, the safety of XMT-2056 has been assessed at level 1. This suggests that there is currently limited knowledge about this drug's efficacy and security."
How extensive is this research experiment in terms of its participant numbers?
"Affirmative. Clinicaltrials.gov has information that confirms this medical trial is currently recruiting participants, with the original post made on December 1st 2022 and last edited on December 5th 2022. This research necessitates 144 patients from 3 separate locations to complete the study."
What is the specific goal of this experiment?
"According to the trial sponsor, Mersana Therapeutics, the primary outcome that will be assessed over a 3 year period is Frequency of Dose-Limiting Toxicities (DLTs) associated with XMT-2056 during the first cycle of treatment. As for secondary outcomes, this study aims to measure Objective Response Rate (ORR), Area under Concentration-Time Curve (AUC), and Volume of Distribution."
Share this study with friends
Copy Link
Messenger